Clinical study of S-1108 in respiratory and urinary tract infections, and its concentration in pleural fluid

概要

論文の詳細を見る
The clinical efficacy and safety of S-1108, a new oral cephalosporin antibiotic, were studied in 15 patients with pneumonia, and respiratory and urinary tract infections. The drug was given in a dose of 300mg daily for an average of 12.6 days.<BR>The clinical response in 15 patients, 11 with respiratory tract infections and 4 with urinary tract infections, was excellent in 1, good in 13, and fair in 1. The overall efficacy rate was 93.3%(14/15).<BR>No side effects were detected. A mild elevation of serum GPT was observed in 1 patient, eosinophilia in 2, and CK and aldolase elevations in 1.<BR>The pleural fluid concentrations of S-1006 after a single oral 200 mg dose were analyzed in 3 patients with carcinomatous pleurisy. The peak concentration was 0.90 μg/ml (mean level) at five hours after administration. The ratio of mean peak pleural fluid level to mean peak serum level was 0.75 (0.90/1.20), and the penetration of S-1006 into pleural fluid was remarkably good.
公益社団法人日本化学療法学会の論文